Publicações 2016 (I):The mc2-CMX vaccine induces an enhanced immune response against Mycobacterium tuberculosiscompared to BCG but with similar lung inflammatory effects
Nossos trabalhos com vacina continuam rendendo frutos. A vacina recombinante MC2-CMX que vem sendo estudada
como uma vacina para tuberculose teve mais uma trabalho publicado pelo grupo. Sua primeira publicação, de autoria
principal da Professora Doutora Ana Paula pode ser acessada pelo link:
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0078639
Em complemento a esse trabalho, o aluno de doutorado Fábio Muniz de Oliveira e colaboradores acabam de ter seu trabalho
aceito na renomada revista brasileira "Memórias do Instituto Oswaldo Cruz", a melhor revista brasileira na área.
O trabalho tem financiamento da CNPq, CAPES, FAPEG.
Abaixo o resumo do trabalho, que ainda não teve sua publicação online liberada.
Title: The mc2-CMX vaccine induces an enhanced immune response against Mycobacterium tuberculosiscompared to BCG but with similar lung inflammatory effects
Although the attenuated Mycobacterium bovis BCG vaccine has been used since 1921, tuberculosis control still proceeds at a slow pace. The main reason is the variable efficacy of BCG protection against tuberculosis among adults, which ranges from 0 to 80%. Subsequently, the mc2-CMX vaccine was developed, with promising results. Nonetheless, this recombinant vaccine needs to be compared to the standard BCG vaccine. The objective of this study was to evaluate the immune response induced by mc2-CMX and compare it to the response generated by BCG. BALB/c mice were immunized with both vaccines and challenged with M. tuberculosis. The immune and inflammatory responses were evaluated by ELISA, flow cytometry and histopathology.Mice vaccinated with mc2-CMX and challenged with Mycobacterium tuberculosis induced an increase in the IgG1 and IgG2 levels againstCMX as well as recalled specific CD4+ T cells that produced Th1 cytokines in the lungs and spleen compared with BCG vaccinated and challenged mice. Both vaccines reduced the lung inflammatory pathology induced by the M. tuberculosis infection. The mc2-CMX vaccine induces a humoral and cellular response that is superior to BCG and is efficiently recalled after challenge with M. tuberculosis, although both vaccines induced similar inflammatory reductions.